SPONSOR
Tianjin Medical University Cancer Institute and Hospital
Total Trials
13
Recruiting
13
Phases
Phase 3, Phase 2, Phase 4
Conditions studied: Pancreatic Cancer, AdultNSCLC Stage IVEGFR Gene MutationExtensive Stage Small Cell Lung Cancer (ES-SCLC)Non-small-cell Lung CancerAdvanced Rectal CancerIREUterine Cervical NeoplasmsEsophageal CancerBreast Cancer
Tianjin Medical University Cancer Institute and Hospital is a clinical research sponsor with 13 registered studies on ClinicalTrials.gov, of which 13 are actively recruiting participants. Research covers conditions including Pancreatic Cancer, Adult, NSCLC Stage IV, EGFR Gene Mutation, Extensive Stage Small Cell Lung Cancer (ES-SCLC).
The trial portfolio spans Phase 3, Phase 2, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Tianjin Medical University Cancer Institute and Hospital
How many clinical trials has Tianjin Medical University Cancer Institute and Hospital sponsored?
ClinicalMetric currently tracks 13 clinical trials sponsored by Tianjin Medical University Cancer Institute and Hospital, of which 13 are actively recruiting participants. These trials cover conditions including Pancreatic Cancer, Adult, NSCLC Stage IV, EGFR Gene Mutation. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Tianjin Medical University Cancer Institute and Hospital research focus on?
Tianjin Medical University Cancer Institute and Hospital clinical trials span Pancreatic Cancer, Adult, NSCLC Stage IV, EGFR Gene Mutation, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Non-small-cell Lung Cancer, and additional conditions. The research pipeline includes Phase 3, Phase 2, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Tianjin Medical University Cancer Institute and Hospital clinical trial?
To participate in a Tianjin Medical University Cancer Institute and Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Tianjin Medical University Cancer Institute and Hospital trials with current recruitment status updated daily.
Clinical Trials by Tianjin Medical University Cancer Institute and Hospital
NCT07436741 Phase 3
Recruiting
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Pancreatic Cancer, Adult
NCT07548060 Phase 2
Recruiting
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
NSCLC Stage IV
NCT06853678
Recruiting
Second-line Immunotherapy for ES-SCLC
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
NCT06141226 Phase 2
Recruiting
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
Non-small-cell Lung Cancer
NCT07281157 Phase 2
Recruiting
Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer
Advanced Rectal Cancer
NCT07799922
Recruiting
IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
IRE
NCT07776821 Phase 4
Recruiting
An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.
Uterine Cervical Neoplasms
NCT07038629 Phase 2
Recruiting
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Esophageal Cancer
NCT07350928 Phase 3
Recruiting
Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status
Breast Cancer
NCT06944106 Phase 2
Recruiting
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Pancreatic Cancer
NCT07475026 Phase 3
Recruiting
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
HCC - Hepatocellular Carcinoma
NCT07801287 Phase 2
Recruiting
Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
HCC - Hepatocellular Carcinoma
NCT05651672 Phase 2
Recruiting
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Gastrointestinal Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology